Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy (CREATE)
Phase IV Study of the Pharmacokinetics of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women With HIV in the United States
Phase IV, multi-site, open-label, non-randomized study of the pharmacokinetics (PK) of long-acting injectable cabotegravir and rilpivirine (CAB LA + RPV LA) during pregnancy and postpartum.
調査の概要
詳細な説明
Up to 40 adult-participants with HIV viral suppression will be enrolled, in pairs with their infants, to achieve 30 evaluable adult-participants overall.
The study will include women who initiated CAB LA + RPV LA outside the study, prior to study entry, either pre-conception (including on the day of conception) or post-conception.
研究の種類
観察的
入学 (推定)
40
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前：Lisa Levy
- 電話番号：2028848480
- メール：LLEVY@FHI360.ORG
研究場所
-
-
California
-
La Jolla、California、アメリカ、92093
- Site 4601, University of California, UC San Diego CRS
-
コンタクト：
- Stephen Spector, MD
- 電話番号：858-534-7055
- メール：saspector@ucsd.edu
-
Los Angeles、California、アメリカ、90033
- Site 5048, University of Southern California
-
コンタクト：
- Alice Stek, MD
- 電話番号：323-226-3353
- メール：stek@usc.edu
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- Site 5052, University of Colorado
-
コンタクト：
- Lisa Abuogi, MD
- 電話番号：303-358-5061
- メール：Lisa.Abuogi@childrenscolorado.org
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- Site 5030, Emory University School of Medicine
-
コンタクト：
- Martina Badell, MD
- 電話番号：404-778-3401
- メール：mbadell@emory.edu
-
-
Illinois
-
Chicago、Illinois、アメリカ、60614
- Site 4001, Lurie Children's Hospital of Chicago CRS
-
コンタクト：
- Jennifer Jao, MD, MPH
- 電話番号：312-227-4080
- メール：jjao@luriechildrens.org
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- Site 5092, Johns Hopkins University
-
コンタクト：
- Allison Agwu, MD
- 電話番号：410-614-3917
- メール：ageorg10@jhmi.edu
-
-
New York
-
The Bronx、New York、アメリカ、10461
- Site 5013, Jacobi Medical Center Bronx
-
コンタクト：
- Andrew Wiznia, MD
- 電話番号：718-918-4664
- メール：andrew.wiznia@einsteinmed.edu
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- Site 6201, University of Pennsylvania
-
コンタクト：
- William Short, MD
- 電話番号：267-971-3275
- メール：william.short@pennmedicine.upenn.edu
-
-
Tennessee
-
Memphis、Tennessee、アメリカ、38105
- Site 6501, St Jude Children's Research Hospital
-
コンタクト：
- Katherine Knapp, MD
- 電話番号：901-595-4645
- メール：katherine.knapp@stjude.org
-
-
Texas
-
Houston、Texas、アメリカ、77030
- Site 5128, Baylor College of Medicine/Texas Children's Hospital
-
コンタクト：
- Mary Paul, MD
- 電話番号：832-822-1038
- メール：mpaul@bcm.edu
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
いいえ
サンプリング方法
非確率サンプル
調査対象母集団
Pregnant women with HIV viral suppression in the United States, age 18 years and older, who initiated CAB LA + RPV LA pre- or post-conception, with an estimated gestational age from 10 0/7 weeks through 23 6/7 weeks at time of entry, and their infants.
説明
Inclusion Criteria:
- Willing and able to provide written informed consent for study participation for self and infant
- At screening, age 18 years or older
- Has a viable, intrauterine, singleton pregnancy with fetal ultrasound with an estimated gestational age (EGA) between 10 0/7 and 23 6/7 weeks (inclusive) at entry
- At entry, intending to deliver at a study-associated medical facility and remain in the geographic area of the study for the duration of anticipated follow-up
- Was diagnosed with HIV prior to the current pregnancy
- Has a documented plasma HIV RNA result less than 50 copies/mL from a specimen collected within 28 days prior to entry
- Has the following laboratory test results from a specimen collected within 28 days prior to entry (1) Grade 2 or lower platelets (greater than or equal to 50,000 cells/mm3 or greater than or equal to 50.00 x 109 cells/L); (2) Grade 1 or lower ALT (less than 2.5 x upper limit of normal; (3) Grade 1 or lower aspartate aminotransferase (AST)
- Received first dose of CAB LA + RPV LA prior to entry (before or after conception of the current pregnancy) and is expected to receive CAB LA + RPV LA on a Q4W schedule for the duration of study participation
Exclusion Criteria:
- History of treatment/virologic failure associated with documented or suspected viral resistance to CAB or RPV (including oral RPV)
- Has any of the following (1) HIV Subtype A6; (2) History of hypersensitivity reaction (HSR), known or suspected allergy to drugs under study, or any other contraindication to CAB or RPV; (3) Current contraindication to IM injection such as a current inflammatory skin condition that compromises the safety of IM injections or a dermatological condition which may interfere with the interpretation of ISRs; (4) Current use or anticipated need of therapeutic anticoagulation; (5) History of known or suspected bleeding disorder; (6) Current severe hepatic impairment (Class C) as determined by Child-Pugh classification; (7) History of suicidal ideation or attempt within six months of entry; (8) History of unstable or poorly controlled seizure disorder; (9) Current tuberculosis infection; (10) Current cervical intraepithelial neoplasia (CIN) 2 or 3, or malignancy other than Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma
- Has any of the following during the current pregnancy: (1) Abnormal placentation, including placenta previa (complete) and placenta accreta/increta/percreta; (2) Cervical cerclage/cervical incompetence; (3) Abnormal fetal anatomy
- Had any of the following in a previous pregnancy: (1) Eclampsia/Hemolysis, Elevated Liver enzymes and Low Platelets (HELLP) syndrome; (2) Intrauterine fetal demise (EGA greater than 20 weeks) without known nonrecurrent etiology; (3) Spontaneous very preterm delivery (less than 32 weeks); (4) Very LBW (less than 1500 g); (5) Cervical or abdominal cerclage due to cervical incompetence
- Receipt of any prohibited medication within seven days prior to entry
- Enrolled in another clinical trial of an investigational agent, device, or vaccine that may impact the PK of CAB or RPV
- Receipt of an investigational agent or chemotherapy within 30 days prior to study entry
- Adult-participant or fetus has any condition, such as uncontrolled diabetes, hypertension, or other comorbidities, that, in the opinion of the site investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Population PK: geometric mean clearance of CAB and RPV in second trimester, third trimester, and postpartum derived from a population PK model
時間枠：Measured from study entry through six weeks postpartum
|
Population PK: geometric mean clearance of CAB and RPV in second trimester, third trimester, and postpartum derived from a population PK model
|
Measured from study entry through six weeks postpartum
|
|
Geometric mean pharmacokinetic trough of CAB and RPV from every 4 week (Q4W) CAB LA and RPV LA measured every 4 weeks in plasma in second trimester, third trimester, and postpartum
時間枠：Measured from study entry through six weeks postpartum
|
Geometric mean pharmacokinetic trough of CAB and RPV from every 4 week (Q4W) CAB LA and RPV LA measured every 4 weeks in plasma in second trimester, third trimester, and postpartum
|
Measured from study entry through six weeks postpartum
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of adult participants with HIV RNA less than 50 copies/mL at delivery
時間枠：Delivery
|
Percentage of adult participants with HIV RNA less than 50 copies/mL at delivery
|
Delivery
|
|
Percentage of adult participants with virologic escape
時間枠：Measured from study entry through six weeks postpartum
|
Percentage of adult participants with virologic escape, defined as a single measurement of HIV RNA greater than or equal to 200 copies/mL
|
Measured from study entry through six weeks postpartum
|
|
Percentage of adult participants with confirmed virologic failure
時間枠：Through 6 weeks postpartum
|
Percentage of adult participants with confirmed virologic failure, defined as two successive HIV RNA test results greater than or equal to 200 copies/mL from separate specimens collected at least two weeks apart
|
Through 6 weeks postpartum
|
|
Number of adult participants with HIV resistance to CAB or RPV who had confirmed virologic failure
時間枠：Through 6 weeks postpartum
|
Number of adult participants with HIV resistance to CAB or RPV using IAS-USA, in participants who experienced confirmed virologic failure
|
Through 6 weeks postpartum
|
|
Number of infant participants with perinatal transmission
時間枠：Birth and six weeks post-birth
|
Number of infant participants with perinatal transmission
|
Birth and six weeks post-birth
|
|
Percentage of adult participants with at least one Grade 3 or higher adverse event
時間枠：Measured from study entry through six weeks postpartum
|
Percentage of adult participants with at least one Grade 3 or higher adverse event
|
Measured from study entry through six weeks postpartum
|
|
Percentage of adult participants with at least one serious adverse event
時間枠：Measured from study entry through six weeks postpartum
|
Percentage of adult participants with at least one serious adverse event
|
Measured from study entry through six weeks postpartum
|
|
Percentage of infant participants with at least one serious adverse event
時間枠：Measured from birth through six weeks post-birth
|
Percentage of infant participants with at least one serious adverse event
|
Measured from birth through six weeks post-birth
|
|
Percentage of adult participants with spontaneous abortion
時間枠：Through 6 weeks postpartum
|
Percentage of adult participants with spontaneous abortion less than 20 weeks gestation
|
Through 6 weeks postpartum
|
|
Percentage of adult participants with fetal demise/stillbirth
時間枠：Through 6 weeks postpartum
|
Percentage of adult participants with fetal demise/stillbirth, at greater than or equal to 20 weeks gestation
|
Through 6 weeks postpartum
|
|
Percentage of infant participants born small for gestational age
時間枠：Birth
|
Percentage of infant participants born small for gestational age, where birthweight is less than 10th percentile for sex and gestational age assigned at birth, based on Intergrowth 21st Standards
|
Birth
|
|
Percentage of infant participants with low birth weight
時間枠：Birth
|
Percentage of infant participants with low birth weight, defined as less than 2500 grams
|
Birth
|
|
Percentage of infant participants born preterm
時間枠：Birth
|
Percentage of infant participants born preterm, defined as less than 37 weeks gestation
|
Birth
|
|
Percentage of mother-infant pairs with occurrence of any adverse pregnancy outcome
時間枠：Through 6 weeks postpartum
|
Percentage of mother-infant pairs with occurrence of any adverse pregnancy outcome.
Outcomes include: spontaneous abortion (<20 weeks gestation), stillbirth (≥20 weeks gestation), preterm delivery (<37 gestational weeks), small for gestational age (<10th percentile per INTERGROWTH 21st Standards), or neonatal death
|
Through 6 weeks postpartum
|
|
Percentage of infant participants with a congenital anomaly
時間枠：Birth
|
Percentage of infant participants with a congenital anomaly based on the Metropolitan Atlanta Congenital Defects Program (MACDP) definition of defect
|
Birth
|
|
Percentage of infant deaths
時間枠：Measured from birth through six weeks post-birth
|
Percentage of infant deaths
|
Measured from birth through six weeks post-birth
|
|
Percentage of adult participants who would recommend CAB LA and RPV LA injections for other people living with HIV during pregnancy
時間枠：Six weeks postpartum
|
Percentage of adult participants who would recommend CAB LA and RPV LA injections
|
Six weeks postpartum
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
協力者
捜査官
- スタディチェア：Rachel Scott, MD, MPH、MedStar Washington Hospital Center & MedStar Health Research Institute
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (推定)
2026年10月15日
一次修了 (推定)
2028年3月22日
研究の完了 (推定)
2028年3月22日
試験登録日
最初に提出
2026年5月27日
QC基準を満たした最初の提出物
2026年6月9日
最初の投稿 (実際)
2026年6月10日
学習記録の更新
投稿された最後の更新 (実際)
2026年8月27日
QC基準を満たした最後の更新が送信されました
2026年8月26日
最終確認日
2026年8月1日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- IMPAACT 2050
- UM1AI068632 (米国 NIH グラント/契約)
- UM1AI068616 (米国 NIH グラント/契約)
- UM1AI106716 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
はい
IPD プランの説明
Individual participant data that underlie results in the publication, after deidentification.
IPD 共有時間枠
Beginning 3 months following publication and available throughout period of funding of the International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) Network by NIH.
IPD 共有アクセス基準
- With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the IMPAACT Network.
- For what types of analyses? To achieve aims in the proposal approved by the IMPAACT Network.
- By what mechanism will data be made available? Researchers may submit a request for access to data using the IMPAACT "Data Request" form at: https://www.impaactnetwork.org/studies/submit-research-proposal. Researchers of approved proposals will need to sign an IMPAACT Data Use Agreement before receiving the data.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
はい
米国FDA規制機器製品の研究
いいえ
米国で製造され、米国から輸出された製品。
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。